Cervical Dysplasia Epidemiology Forecast 2025-2034

Cervical dysplasia refers to a precancerous condition in which the growth of abnormal cells can be found on the surface of the cervix. It is estimated that around 250,000 to 1 million cisgender women are diagnosed with cervical dysplasia every year in the United States, with a high prevalence reported among women aged between 25 to 35 years.

Cervical Dysplasia Epidemiology Forecast Report Coverage

The “Cervical Dysplasia Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of cervical dysplasia. It projects the future incidence and prevalence rates of cervical dysplasia across various populations. The study covers age and type as major determinants of the cervical dysplasia-affected population. The report highlights patterns in the prevalence of cervical dysplasia over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of cervical dysplasia in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Cervical Dysplasia: Disease Overview

In cervical dysplasia (or cervical intraepithelial neoplasia), the growth of abnormal cells occurs on the surface of the cervix. Early detection and treatment can prevent the progression of these cells from becoming cancerous. Cervical dysplasia is classified into CIN 1, CIN 2, and CIN 3, with CIN 2 and 3 often requiring treatment to prevent cancer. An individual can develop cervical dysplasia if they get infected with human papillomavirus.

Cervical Dysplasia: Treatment Overview

Treatment for cervical dysplasia depends on the severity of the condition, treatment preferences, and patient’s profile. For mild cervical dysplasia, regular Pap smears and HPV testing are recommended to monitor the changes in the abnormal cells over time. Cryotherapy, loop electrosurgical excision procedure (LEEP), and laser therapy are some of the surgical and ablative treatment options for severe dysplasia or high-grade squamous intraepithelial lesions.

Epidemiology

The cervical dysplasia epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for cervical dysplasia by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for cervical dysplasia and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• As per the systematic review and meta-analysis published in the Indian Journal of Gynecologic Oncology (2023), the prevalence of high-grade and low-grade cervical dysplasia was estimated to be 4.3% and 6.2%, respectively, with the highest prevalence reported in the European continent.
• According to the review published in the Journal of Clinical and Pharmaceutical Research (2022), approximately 570,000 women were diagnosed with cervical dysplasia in 2018.
• Cervical dysplasia is strongly linked to sexually transmitted human papillomavirus (HPV) infection, with some strains like HPV-16 and HPV-18 more likely to cause cervical dysplasia. Researchers estimate that over 75% of sexually active cisgender women are infected with the human papillomavirus at some point during their lives.
• Cervical dysplasia can develop at any age but is most common among women under 30 years of age.

Country-wise Cervical Dysplasia Epidemiology

The cervical dysplasia epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of cervical dysplasia varies significantly between countries owing to the differences in the prevalence of human papillomavirus, vaccination coverage, awareness levels, screening programs, and access to healthcare. In the United States, cervical dysplasia is diagnosed in nearly 250,000 to 1 million cisgender women each year.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of cervical dysplasia based on several factors.
• Cervical Dysplasia Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of cervical dysplasia are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of cervical dysplasia epidemiology in the 8 major markets?
• What will be the total number of patients with cervical dysplasia across the 8 major markets during the forecast period?
• What was the country-wise prevalence of cervical dysplasia in the 8 major markets in the historical period?
• Which country will have the highest number of cervical dysplasia patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of cervical dysplasia during the forecast period of 2025-2034?
• What are the currently available treatments for cervical dysplasia?
• What are the disease risks, signs, symptoms, and unmet needs of cervical dysplasia?

This product will be delivered within 3-5 business days.